
An experimental drug helped mice resist cancers their immune systems had never encountered, raising the possibility that treating one tumor could someday help protect against others.
Pancreatic cancer remains one of the most difficult cancers to treat, partly because tumors can wall themselves off from the immune system. Many breast, colon, and lung cancers use the same defense, surrounding themselves with dense, scar-like tissue that keeps cancer-fighting immune cells out. This barrier is one reason immunotherapy, which helps the immune system attack cancer, works for only a minority of patients with solid tumors.
Researchers have now developed an experimental drug that breaks through this barrier in mice. The treatment eliminated aggressive pancreatic tumors in some animals, prevented breast cancer from spreading, and produced lasting immune protection against future cancers.
The study, published November 9, 2026, in Cancer Cell, was led by Seong-Jin Kim, PhD, and scientists at MedPacto, Inc., in Seoul, Korea.
Tumors exploit a molecule the body needs
Tumors build their defenses partly by releasing large amounts of a chemical messenger called TGF-β. This substance encourages nearby cells to produce fibrous tissue while weakening the immune cells that could attack the cancer. Blocking it has proven difficult because TGF-β also performs important functions in healthy tissue. Previous drugs have struggled to suppress enough of it inside tumors without causing unwanted effects elsewhere in the body.
To get around this problem, the team developed a drug called FEBP-sTβRII that carries a molecular tag directing it toward tumors. The tag attaches to a particular form of fibronectin, a protein abundant in many cancers but rarely found in healthy adult tissue. Researchers detected this target in mouse models of breast, colon, lung, liver, prostate, pancreatic, and brain cancers, as well as melanoma, and in many human tumor types.
The targeted drug accumulated inside tumors and remained there for days. Without the tag, the same blocker had little effect on tumors and altered the activity of 693 genes in the blood, compared with just 25 for the targeted treatment.
“This study shows that where you block TGF-β matters as much as whether you block it,” said senior author Kim, who is also affiliated with the GILO Institute.
Tumor support cells join the immune attack
With the protective barrier weakened, cancer-killing T cells could enter the tumors. They released a chemical signal called interferon-gamma, prompting nearby support cells and immune cells to display recognizable pieces of the cancer. This helped the immune system identify its target and sustain the attack. Researchers observed this response in pancreatic tumors and melanoma.
Unlike existing immunotherapies that primarily remove restrictions on T cells, the experimental drug also changes the environment surrounding the cancer, making it easier for immune cells to reach and recognize tumors.
Cancer control and lasting immune memory
The researchers reported several promising results across different mouse experiments:
- Pancreatic cancer: The drug worked in three different mouse models. In one aggressive model, tumors disappeared in 75% of treated mice, and seven of eight were still alive 270 days after treatment ended.
- Triple-negative breast cancer: In a highly metastatic model, the drug slowed tumor growth, prevented spread to the lungs, and extended survival. Standard immunotherapy and untargeted TGF-β blockers gave little or no benefit.
- Combination therapy: Added to an existing immunotherapy drug (anti-PD-1), it nearly eradicated pancreatic tumors that resist that drug alone.
- Lasting memory: Cured mice rejected the same cancer when it was reintroduced months later. Many also rejected bladder and lung tumors they had never encountered.
- Transferable protection: T cells from cured mice protected cancer-free mice against bladder cancer.
“TGF-β helps build the defenses of many solid tumors, so this approach has the potential to reach well beyond a single cancer,” said Dr. Letterio. “By delivering the blocker directly to the tumor, we don’t just open the door to T cells. We appear to be teaching the immune system lessons it remembers long after the tumor is gone, and in some cases those lessons protect against other cancers.”
Study co-author John J. Letterio, MD, PhD, directs the Angie Fowler Adolescent and Young Adult Cancer Institute at University Hospitals Rainbow Babies & Children’s Hospital and the Developmental Therapeutics Program at Case Comprehensive Cancer Center, Case Western Reserve University.
The immune response observed in mice resembled patterns previously seen in patients who responded to immunotherapy for melanoma, gastric cancer, and pancreatic cancer. Measuring the drug’s fibronectin target in tumors might eventually help identify patients most likely to benefit.
A human version of the drug has entered safety testing, with clinical trials planned for 2027 to evaluate its safety and effectiveness in patients whose solid tumors have not responded to standard treatments.
Reference: “A stroma-sensing TGF-β blockade reprograms CAF-myeloid niches to induce durable tumor immunity” by Dong Woo Kang, Jin Beom Bae, Seonho Yoo, Hyejin Kim, Pyunggang Kim, Jaewoo Mo, Jinhwan Kim, Jin Su Kim, Kwiyeom Yoon, Ye Seon Kim, Jeong Su Lee, June Myoung Kim, Min Gi Kang, Min Jung Lee, Changwon Lim, Isaac Y. Kim, Chang Pyo Hong, Junil Kim, John J. Letterio and Seong-Jin Kim, 09 November 2026, Cancer Cell.
DOI: 10.1016/j.ccell.2026.10.007
Disclosure: Dr. Kim is a founder of MedPacto and co-founder of Celloram. Dr. Letterio is a co-founder of Celloram and a member of MedPacto’s clinical advisory board. MedPacto holds pending patents on the drug.
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.